TDMS Study 05158-04 Pathology Tables
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
Facility: Battelle Northwest
Chemical CAS #: 1313-27-5
Lock Date: 07/13/93
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 17 12 14 10
Natural Death 8 6 2 5
Accidently Killed 1 1
Survivors
Terminal Sacrifice 24 31 31 35
Moribund Sacrifice 1 2
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (40) (44) (46) (41)
Carcinoma, Metastatic, Pancreas 1 (2%)
Intestine Small, Duodenum (43) (46) (47) (46)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (44) (45) (47) (46)
Liver (50) (50) (50) (49)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Hemangiosarcoma 2 (4%)
Hepatocellular Carcinoma 17 (34%) 8 (16%) 13 (26%) 5 (10%)
Hepatocellular Carcinoma, Multiple 2 (4%) 4 (8%) 3 (6%) 6 (12%)
Hepatocellular Adenoma 7 (14%) 8 (16%) 7 (14%) 10 (20%)
Hepatocellular Adenoma, Multiple 2 (4%) 3 (6%) 6 (12%) 6 (12%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Mesentery (4) (9) (9) (7)
Carcinoma, Metastatic, Pancreas 1 (11%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (25%)
Teratoma Malignant, Metastatic, Ovary 1 (11%)
Oral Mucosa (1) (1)
Squamous Cell Carcinoma 1 (100%)
Pancreas (50) (49) (48) (46)
Carcinoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (49) (49) (49)
Stomach, Forestomach (50) (50) (49) (47)
Squamous Cell Papilloma 2 (4%)
Stomach, Glandular (49) (49) (47) (46)
Tooth (2)
Odontoma 1 (50%)
Page 2
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (49) (49)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (49)
Adenoma 1 (2%) 1 (2%)
Carcinoma, Metastatic, Pancreas 1 (2%)
Histiocytic Sarcoma 1 (2%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (50) (49) (49) (49)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (49) (48) (46)
Adenoma 1 (2%) 1 (2%)
Carcinoma 1 (2%) 1 (2%)
Pituitary Gland (49) (48) (48) (49)
Pars Distalis, Adenoma 9 (18%) 8 (17%) 9 (19%) 9 (18%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 2 (4%)
Thyroid Gland (50) (50) (49) (49)
Follicular Cell, Adenoma 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Follicular Cell, Adenoma, Multiple 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (49) (48) (46)
Cystadenoma 1 (2%) 2 (4%) 3 (6%)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Luteoma 1 (2%) 1 (2%) 1 (2%)
Teratoma Malignant 1 (2%)
Uterus (50) (50) (49) (49)
Carcinoma 1 (2%)
Page 3
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Polyp Stromal 4 (8%) 3 (6%) 3 (6%)
Sarcoma 1 (2%)
Endometrium, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (49)
Histiocytic Sarcoma 1 (2%)
Lymph Node (4) (6) (7) (4)
Iliac, Teratoma Malignant, Metastatic, Ovary 1 (17%)
Pancreatic, Teratoma Malignant, Metastatic,
Ovary 1 (17%)
Lymph Node, Bronchial (41) (32) (36) (31)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Lymph Node, Mandibular (39) (40) (43) (40)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mesenteric (49) (49) (46) (44)
Carcinoma, Metastatic, Pancreas 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Lymph Node, Mediastinal (41) (41) (40) (41)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Spleen (50) (50) (49) (47)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Thymus (40) (35) (40) (37)
Histiocytic Sarcoma 1 (3%) 1 (3%)
Thymoma Malignant 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (49) (49) (50)
Carcinoma 2 (4%) 1 (2%)
Skin (50) (50) (49) (50)
Melanoma Malignant 1 (2%)
Trichoepithelioma 1 (2%)
Pinna, Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Osteosarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 2 (4%) 4 (8%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (1)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
Teratoma Malignant, Metastatic, Ovary 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (49)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Choroid Plexus, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (49) (49)
Alveolar/Bronchiolar Adenoma 1 (2%) 4 (8%) 8 (16%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 2 (4%) 6 (12%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 3 (6%) 2 (4%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (2%)
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Nose (49) (50) (49) (49)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (2) (1) (1)
Adenoma 2 (67%) 2 (100%)
Carcinoma 1 (33%) 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (47)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Teratoma Malignant, Metastatic, Ovary 1 (2%)
Renal Tubule, Carcinoma 1 (2%)
Page 5
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Urinary Bladder (48) (50) (49) (46)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant 3 (6%) 5 (10%) 8 (16%) 6 (12%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 39 43 40
Total Primary Neoplasms 65 64 75 77
Total Animals with Benign Neoplasms 25 24 30 26
Total Benign Neoplasms 35 36 40 44
Total Animals with Malignant Neoplasms 28 25 29 25
Total Malignant Neoplasms 30 28 35 33
Total Animals with Metastatic Neoplasms 4 4 5 3
Total Metastatic Neoplasm 10 11 9 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 6 4 11 4
Moribund Sacrifice 8 13 14 9
Survivors
Terminal Sacrifice 36 33 25 37
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (43) (40) (38) (43)
Intestine Small, Duodenum (44) (47) (41) (48)
Sarcoma 1 (2%)
Intestine Small, Jejunum (44) (46) (41) (48)
Hemangiosarcoma 1 (2%)
Intestine Small, Ileum (44) (46) (41) (48)
Histiocytic Sarcoma 1 (2%)
Liver (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 9 (18%) 7 (14%) 13 (26%) 10 (20%)
Hepatocellular Carcinoma, Multiple 3 (6%) 11 (22%) 8 (16%) 3 (6%)
Hepatocellular Adenoma 13 (26%) 12 (24%) 15 (30%) 14 (28%)
Hepatocellular Adenoma, Multiple 7 (14%) 3 (6%) 4 (8%) 5 (10%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (2%)
Mesentery (3) (4) (2) (2)
Pancreas (50) (48) (48) (50)
Salivary Glands (50) (50) (49) (50)
Stomach, Forestomach (50) (49) (48) (50)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (50) (48) (46) (49)
Carcinoma 1 (2%)
Tooth (1) (1) (1)
Odontoma 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (48) (50)
Adenoma 1 (2%) 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Adrenal Medulla (50) (49) (48) (50)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (48) (48) (50)
Adenoma 2 (4%) 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (47) (47) (46) (47)
Pars Intermedia, Adenoma 1 (2%) 2 (4%)
Thyroid Gland (50) (50) (49) (50)
Follicular Cell, Adenoma 1 (2%) 3 (6%) 2 (4%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Preputial Gland (49) (50) (48) (50)
Histiocytic Sarcoma 1 (2%)
Prostate (48) (47) (47) (47)
Seminal Vesicle (50) (48) (47) (49)
Testes (50) (50) (49) (50)
Hemangioma 1 (2%)
Bilateral, Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node (2) (3) (2) (2)
Renal, Histiocytic Sarcoma 1 (50%) 1 (33%)
Lymph Node, Bronchial (31) (37) (32) (36)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mandibular (32) (33) (32) (34)
Lymph Node, Mesenteric (46) (47) (45) (48)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Page 9
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mediastinal (34) (37) (39) (34)
Histiocytic Sarcoma 1 (3%)
Spleen (50) (48) (49) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Thymus (30) (35) (32) (36)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (49) (50)
Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (49) (50)
Alveolar/Bronchiolar Adenoma 8 (16%) 13 (26%) 10 (20%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 9 (18%) 13 (27%) 7 (14%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 7 (14%) 1 (2%) 3 (6%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 5 (10%) 2 (4%) 6 (12%) 3 (6%)
Histiocytic Sarcoma 1 (2%)
Nose (50) (50) (49) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Histiocytic Sarcoma 1 (100%)
Harderian Gland (3) (4) (4) (3)
Adenoma 1 (33%) 4 (100%) 4 (100%) 2 (67%)
Carcinoma 2 (67%) 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (49) (50)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (50) (49) (46) (49)
Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 4 (8%) 1 (2%)
Lymphoma Malignant 2 (4%) 2 (4%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:24
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 40 44 45 42
Total Primary Neoplasms 55 83 83 66
Total Animals with Benign Neoplasms 28 26 28 28
Total Benign Neoplasms 32 41 41 36
Total Animals with Malignant Neoplasms 20 36 35 24
Total Malignant Neoplasms 23 42 42 30
Total Animals with Metastatic Neoplasms 6 2 7 4
Total Metastatic Neoplasm 6 2 7 5
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------